Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent

AIDS

Volumn 12, Issue 10, 1998, Pages 1129-1138

  Balzarini, Jan ^a   Naesens, Lieve ^a   Verbeken, Eric ^b   Laga, Marie ^c   Van Damme, Lut ^c   Parniak, Michael ^d   Van Mellaert, Lieve ^a   Anné, Jozef ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

AIDS; HIV; Microbicide; Non nucleoside RT inhibitor; Reverse transcriptase (RT); Thiocarboxanilide UC 781; Virucide

Indexed keywords

ANTIVIRUS AGENT; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOCARBOXANILIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GEL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVAGINAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; VAGINA FLORA; VAGINA MUCOSA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, INTRAVAGINAL; ANILIDES; ANIMALS; ANTI-HIV AGENTS; BACTERIA; CANDIDA; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA VIRUSES; DRUG STABILITY; FEMALE; FURANS; GELS; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; MICROBIAL SENSITIVITY TESTS; RABBITS; REVERSE TRANSCRIPTASE INHIBITORS; RNA VIRUSES; TEMPERATURE; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 0032500021     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199810000-00004     Document Type: Article

References (26)

1. De Clercq E: Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Exp Opin Invest Drugs 1994, 3:253-271.
2. De Clercq E: Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995, 8:200-239.
3. Mellors JW, Larder BA, Schinazi RF: Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News 1995, 3:8-13.
4. Elias CJ, Coggins C: Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996, 10 (suppl 3):S43-S51.
5. Perriëns J, Van Damme L: Vaginal microbicide research finally coming of age. UNAIDS Newsletter 1996, 5:8-9.
6. Elias CJ, Heise LL: Challenges for the development of female-controlled vaginal microbicides. AIDS 1994, 8:1-9.
7. The International Working Group on Vaginal Microbicides: Recommendations for the development of vaginal microbicides. AIDS 1996, 10:UNAIDS1-UNAIDS6.
8. Pauwels RA, De Clercq E: Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:211-221.
9. Malkovsky M, Newell A, Dalgleish AG: Inactivation of HIV by nonoxynol-9 [letter]. Lancet 1998, i:645.
10. Hicks DR, Martin LA, Getchell JP, et al.: Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 1985, ii:1422-1423.
11. Zekeng L, Feldblum PJ, Oliver RM, Kapute L: Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993, 7:725-731.
12. Feldblum P, Hira S, Goodwin S, Kamanga J, Mukelabaie G: Efficacy of spermicide use and condom use by HIV-discordant couples in Zambia. VIII International Conference on AIDS/III STD World Congress. Amsterdam, July 1992 [abstract WeC1085].
13. Kreiss J, Ngugi E, Holmes K, et al.: Efficacy of nonoxynol-9-contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268:477-482.
14. Roddy RE, Zekeng L, Ryan KA, Tamoufe A, Weir SS: A randomized controlled trial of the effect of nonoxynol-9 film use on male-to-female transmission of HIV-1. National Conference on Women and HIV. Pasadena, May 1996 [abstract 215.3].
15. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997, 71:3023-3030.
16. Parniak MA, Balzarini J: The thiocarboxanilide UC-781, a virucidal agent? Int Antiviral News 1997, 5:205-206.
17. Barnard J, Borkow G, Parniak MA: The thiocarboxanilide nonnucleoside UC-781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997, 36:7786-7792.
18. Bader JP, McMahon JB, Schultz RJ, et al.: Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci USA 1991, 88:6740-6744.
19. Balzarini J, Brouwer WG, Felauer EE, De Clercq E, Karlsson A: Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res 1995, 27:219-236.
20. Balzarini J, Brouwer WG, Dao DC, Osika EM, De Clercq E: Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 (HIV-1) strains at a similar potency as wild-type virus. Antimicrob Agents Chemother 1996, 40:1454-1466.
21. Balzarini J, Pérez-Pérez M-J, Velázquez S, et al.: Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc Natl Acad Sci USA 1995, 92:5470-5474.
22. Balzarini J, Pelemans H, Aquaro S, et al.: Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 1996, 50:394-401.
23. Esnouf RM, Stuart DI, De Clercq E, Schwartz E, Balzarini J: Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem Biophys Res Commun 1997, 234:458-464.
24. Vandamme L, Niruthisard S, Atisook R, et al.: Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998, 12:433-437.
25. Popovic M, Sarngadharan MG, Read E, Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
26. Balzarini J, Pérez-Pérez M-J, San-Félix A, et al.: Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2′, 2′-dioxide)thymine (TSAO-T). J Biol Chem 1992, 267:11831-11838.